{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T13:01:50Z","timestamp":1781614910147,"version":"3.54.5"},"reference-count":14,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T00:00:00Z","timestamp":1742774400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100000568","name":"British Society for Rheumatology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000568","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To explore the extent to which skin severity is reflected in the Psoriatic Arthritis Disease Activity Score (PASDAS).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Cross-sectional baseline data from the British Society for Rheumatology PsA register (BSR-PsA) and the GRAPPA Composite Exercise (GRACE) dataset was included. The body surface area score (BSA) and the Dermatology Life Quality Index (DLQI) were used to assess skin disease activity. BSA was categorized as none (0%), mild (&amp;lt;3%), moderate (3\u201310%) and severe (&amp;gt;10%) skin involvement. DLQI was categorized as no (0\u20131), small (2\u20135), moderate (6\u201310), large (11\u201320) and extreme (21\u201330) effect on quality of life. Mean and standard deviation PASDAS scores, physician and patient global VAS scores were calculated for each category of skin severity by both BSA and DLQI. Within each cohort, two groups were created based on the severity of skin disease (BSA cut-off of 10). Propensity score matching was applied to match groups for musculoskeletal disease activity and differences between the groups were assessed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In both the BSR-PsA (N\u2009=\u20091126) and GRACE (N\u2009=\u2009588) datasets, PASDAS, VAS physician global and VAS patient global scores increased with increasing skin scores. For the subjects grouped by severity of skin involvement, and matched for musculoskeletal activity, significant differences in PASDAS, physician global score and DLQI were observed for the BSR-PsA, and physician and patient global scores, DLQI and age for the GRACE dataset.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>These data suggest that psoriasis disease activity is represented in the composite PASDAS score, possibly through the global (patient and physician) VAS scores.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaf161","type":"journal-article","created":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T04:06:11Z","timestamp":1743134771000},"page":"3478-3482","source":"Crossref","is-referenced-by-count":2,"title":["Exploring the relationship between skin severity and PASDAS in psoriatic arthritis: a cross-sectional study in the BSR-PsA and GRACE cohorts"],"prefix":"10.1093","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5320-5702","authenticated-orcid":false,"given":"Michelle L M","family":"Mulder","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Radboud University Medical Centre , Nijmegen,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0016-7591","authenticated-orcid":false,"given":"Gareth T","family":"Jones","sequence":"additional","affiliation":[{"name":"Aberdeen Centre for Arthritis and Musculoskeletal Health (Epidemiology Group), University of Aberdeen , Aberdeen,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1865-5390","authenticated-orcid":false,"given":"Ovidiu","family":"Rotariu","sequence":"additional","affiliation":[{"name":"Aberdeen Centre for Arthritis and Musculoskeletal Health (Epidemiology Group), University of Aberdeen , Aberdeen,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4155-9105","authenticated-orcid":false,"given":"Philip S","family":"Helliwell","sequence":"additional","affiliation":[{"name":"Leeds Institute of Rheumatology and Musculoskeletal Medicine, University of Leeds , Leeds,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,3,24]]},"reference":[{"key":"2025052703542380100_keaf161-B1","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1056\/NEJMra1505557","article-title":"Psoriatic arthritis","volume":"376","author":"Ritchlin","year":"2017","journal-title":"N Engl J Med"},{"key":"2025052703542380100_keaf161-B2","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/art.40391","article-title":"Group for research and assessment of psoriasis and psoriatic arthritis\/outcome measures in rheumatology consensus-based recommendations and research agenda for use of composite measures and treatment targets in psoriatic arthritis","volume":"70","author":"Coates","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2025052703542380100_keaf161-B3","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1136\/annrheumdis-2012-201341","article-title":"The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project)","volume":"72","author":"Helliwell","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2025052703542380100_keaf161-B4","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.3899\/jrheum.140172","article-title":"Composite disease activity and responder indices for psoriatic arthritis: a report from the GRAPPA 2013 meeting on development of cutoffs for both disease activity states and response","volume":"41","author":"Helliwell","year":"2014","journal-title":"J Rheumatol"},{"key":"2025052703542380100_keaf161-B5","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.1093\/rheumatology\/keac025","article-title":"Defining the minimal important change (MIC) and meaningful change value (MCV) for the Psoriatic Arthritis Disease Activity Score (PASDAS) in a routine practice cohort of patients with psoriatic arthritis","volume":"61","author":"Mulder","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2025052703542380100_keaf161-B6","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1093\/rheumatology\/kez215","article-title":"Comparison of disease activity measures in early psoriatic arthritis in usual care","volume":"58","author":"Wervers","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2025052703542380100_keaf161-B7","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1136\/annrheumdis-2016-210242","article-title":"International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials","volume":"76","author":"Orbai","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2025052703542380100_keaf161-B8","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1136\/ard-2024-225531","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update","volume":"83","author":"Gossec","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2025052703542380100_keaf161-B9","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021","volume":"18","author":"Coates","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"2025052703542380100_keaf161-B10","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s41927-021-00189-0","article-title":"The BSR-PsA: study protocol for the British Society for Rheumatology psoriatic arthritis register","volume":"5","author":"Jones","year":"2021","journal-title":"BMC Rheumatol"},{"key":"2025052703542380100_keaf161-B11","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1136\/annrheumdis-2017-211137","article-title":"The dynamics of response as measured by multiple composite outcome tools in the TIght COntrol of inflammation in early Psoriatic Arthritis (TICOPA) trial","volume":"76","author":"Coates","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2025052703542380100_keaf161-B12","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI)\u2014a simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"key":"2025052703542380100_keaf161-B13","doi-asserted-by":"crossref","first-page":"528105","DOI":"10.1155\/2014\/528105","article-title":"Disease activity in psoriatic arthritis: comparison of the discriminative capacity and construct validity of six composite indices in a real world","volume":"2014","author":"Salaffi","year":"2014","journal-title":"Biomed Res Int"},{"key":"2025052703542380100_keaf161-B14","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1093\/rheumatology\/keaa766","article-title":"Measuring disease activity in psoriatic arthritis: PASDAS implementation in a tightly monitored cohort reveals residual disease burden","volume":"60","author":"Mulder","year":"2021","journal-title":"Rheumatology (Oxford)"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keaf161\/62574834\/keaf161.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/6\/3478\/62574834\/keaf161.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/6\/3478\/62574834\/keaf161.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T07:54:36Z","timestamp":1748332476000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/6\/3478\/8092565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,24]]},"references-count":14,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,3,24]]},"published-print":{"date-parts":[[2025,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaf161","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2025,3,24]]}}}